114 results on '"Dalm, Virgil A.S.H."'
Search Results
2. The association of inflammatory markers with frailty and in-hospital mortality in older COVID-19 patients
- Author
-
Mooijaart, Simon P., Gussekloo, Jacobijn, Polinder-Bos, Harmke A., Moons, Karel G.M., van Smeden, Maarten, Peeters, Geeske, Melis, René J.F., Elders, Petra J.M., Festen, Jan, van der Linden, Carolien M.J., Jansen, Steffy W.M., Willems, Hanna C., van der Bol, Jessica M., Appelman, Brent, Rusch, Daisy, van den Oever, Niels C. Gritters, Simsek, Suat, van Osch, Frits H.M., de Kruif, Martijn D., Douma, Renée A., Moeniralam, Hazra, Brinkman, Kees, Bokhizzou, Nejma, Leavis, Helen, Beudel, Martijn, Abbink, Evertine J., Jacobs-Peters, Jeannette, Dofferhoff, Ton, Hoogerwerf, Jacobien J., Kerckhoffs, Angele, van der Maat, Josephine, Netea, Mihai, Slieker, Kitty, Veerman, Karin, Tran Van Hoi, Estelle, Mooijaart, Simon, Dalm, Virgil A.S.H., Polinder Bos, Harmke A., van Heemst, Diana, van Raaij, Bas F.M., Noordam, Raymond, Kuranova, Anna, and Smorenberg, Annemieke
- Published
- 2024
- Full Text
- View/download PDF
3. Serum immunoglobulin levels and risk of antibiotic prescription in middle-aged and older individuals: A population-based cohort study
- Author
-
Vanoverschelde, Anna, Khan, Samer R., Dalm, Virgil A.S.H., Chaker, Layal, Brusselle, Guy, Stricker, Bruno H., and Lahousse, Lies
- Published
- 2023
- Full Text
- View/download PDF
4. Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination
- Author
-
Geers, Daryl, Sablerolles, Roos S.G., van Baarle, Debbie, Kootstra, Neeltje A., Rietdijk, Wim J.R., Schmitz, Katharina S., Gommers, Lennert, Bogers, Susanne, Nieuwkoop, Nella J., van Dijk, Laura L.A., van Haren, Eva, Lafeber, Melvin, Dalm, Virgil A.S.H., Goorhuis, Abraham, Postma, Douwe F., Visser, Leo G., Huckriede, Anke L.W., Sette, Alessandro, Grifoni, Alba, de Swart, Rik L., Koopmans, Marion P.G., van der Kuy, P. Hugo M., GeurtsvanKessel, Corine H., and de Vries, Rory D.
- Published
- 2023
- Full Text
- View/download PDF
5. Granulomas in common variable immunodeficiency display different histopathological features compared to other granulomatous diseases
- Author
-
Stigt, Astrid C., primary, Thüsen, Jan H., additional, Mustafa, Dana A.M., additional, Bosch, Thierry P.P., additional, Lila, Karishma A., additional, Vadgama, Disha, additional, Hagen, Martin van, additional, Dalm, Virgil A.S.H., additional, Dik, Willem. A., additional, and IJspeert, Hanna, additional
- Published
- 2024
- Full Text
- View/download PDF
6. Immunologic mechanisms associated with STAT6 gain-of-function variant identified in early-onset allergies
- Author
-
Suratannon, Narissara, primary, Dik, Willem, additional, Israsena, Nipan, additional, Ingrungruanglert, Praewphan, additional, Dalm, Virgil A.S.H., additional, Buranapraditkun, Supranee, additional, Swagemakers, Sigrid, additional, IJspeert, Hanna, additional, van der Spek van der Spek, Peter J., additional, Chatchatee, Pantipa, additional, and van Hagen, Martin, additional
- Published
- 2024
- Full Text
- View/download PDF
7. Human autoinflammatory disease reveals ELF4 as a transcriptional regulator of inflammation
- Author
-
Tyler, Paul M., Bucklin, Molly L., Zhao, Mengting, Maher, Timothy J., Rice, Andrew J., Ji, Weizhen, Warner, Neil, Pan, Jie, Morotti, Raffaella, McCarthy, Paul, Griffiths, Anne, van Rossum, Annemarie M. C., Hollink, Iris H.I.M., Dalm, Virgil A.S.H., Catanzaro, Jason, Lakhani, Saquib A., Muise, Aleixo M., and Lucas, Carrie L.
- Published
- 2021
- Full Text
- View/download PDF
8. High Prevalence of Long COVID in Common Variable Immunodeficiency:An Italian Multicentric Study
- Author
-
Villa, Annalisa, Milito, Cinzia, Deiana, Carla Maria, Gambier, Renato Finco, Punziano, Alessandra, Buso, Helena, Bez, Patrick, Lagnese, Gianluca, Garzi, Giulia, Costanzo, Giulia, Giannuzzi, Gloria, Pagnozzi, Chiara, Dalm, Virgil A.S.H., Spadaro, Giuseppe, Rattazzi, Marcello, Cinetto, Francesco, Firinu, Davide, Villa, Annalisa, Milito, Cinzia, Deiana, Carla Maria, Gambier, Renato Finco, Punziano, Alessandra, Buso, Helena, Bez, Patrick, Lagnese, Gianluca, Garzi, Giulia, Costanzo, Giulia, Giannuzzi, Gloria, Pagnozzi, Chiara, Dalm, Virgil A.S.H., Spadaro, Giuseppe, Rattazzi, Marcello, Cinetto, Francesco, and Firinu, Davide
- Abstract
The long-term effects of SARS-CoV-2 infection represent a relevant global health problem. Long COVID (LC) is defined as a complex of signs and symptoms developed during or after SARS-CoV-2 infection and lasting > 12 weeks. In common variable immunodeficiency (CVID) patients, we previously reported higher risk of hospitalization and death during SARS-CoV-2 infection, as well as prolonged swab positivity and frequent reinfections. The aim of the present study was to assess the risk of LC in an Italian cohort of CVID patients. We used a translated version of the survey proposed by Centers for Disease Control and Prevention (CDC) to collect data on LC. In the enrolled cohort of 175 CVID patients, we found a high prevalence of LC (65.7%). The most frequent LC symptoms were fatigue (75.7%), arthralgia/myalgia (48.7%), and dyspnea (41.7%). The majority of patients (60%) experienced prolonged symptoms, for at least 6 months after infection. In a multivariate analysis, the presence of complicated phenotype (OR 2.44, 95% CI 1.88-5.03; p = 0.015), obesity (OR 11.17, 95% CI 1.37-90.95; p = 0.024), and female sex (OR 2.06, 95% CI 1.09-3.89; p = 0.024) significantly correlated with the development of LC. In conclusion, in this multicenter observational cohort study, we demonstrated that CVID patients present an increased prevalence of LC when compared to the general population. Improved awareness on the risk of LC in CVID patients could optimize management of this new and alarming complication of SARS-CoV-2 infection.
- Published
- 2024
9. A patient-based murine model recapitulates human STAT3 gain-of-function syndrome
- Author
-
Meesilpavikkai, Kornvalee, Zhou, Zijun, Kaikaew, Kasiphak, Phakham, Suphattra, van der Spek, Peter J., Swagemakers, Sigrid, Venter, Deon J., de Bie, Maaike, Schrijver, Benjamin, Schliehe, Christopher, Kaiser, Fabian, Dalm, Virgil A.S.H., van Hagen, P. Martin, Hirankarn, Nattiya, IJspeert, Hanna, and Dik, Willem A.
- Published
- 2024
- Full Text
- View/download PDF
10. Contributors
- Author
-
Abers, Michael S., primary, Babushok, Daria V., additional, Ballow, Mark, additional, Boisson, Bertrand, additional, Bonagura, Vincent Robert, additional, Bonilla, Francisco A., additional, Bosco de Oliveira Filho, João, additional, Boztug, Kaan, additional, Broderick, Lori, additional, Butte, Manish J., additional, Candotti, Fabio, additional, Casanova, Jean-Laurent, additional, Chandrakasan, Shanmuganathan, additional, Condino-Neto, Antonio, additional, Crow, Yanick J., additional, Cunningham-Rundles, Charlotte, additional, Dalm, Virgil A.S.H., additional, de Jesus, Adriana A., additional, de Maio, Emma, additional, de Saint Basile, Geneviève, additional, de Vries, Esther, additional, Dokal, Inderjeet, additional, Duncan, Christopher J.A., additional, Durandy, A., additional, Ehl, Stephan, additional, Etzioni, Amos, additional, Ferguson, Polly J., additional, Fleisher, Thomas A., additional, Forbes-Satter, Lisa R., additional, Frank, Michael M., additional, Freeman, Alexandra F., additional, Frémond, Marie-Louise, additional, Frew, John W., additional, Fusaro, Mathieu, additional, Gambineri, Eleonora, additional, Ganetzky, Rebecca D., additional, Gennery, Andrew R., additional, Goldbach-Mansky, Raphaela, additional, Goldstein, Amy C., additional, Graham, John M., additional, Gupton, Stephanie E., additional, Haddad, Elie, additional, Hambleton, Sophie, additional, Hanson, Eric P., additional, Heimall, Jennifer, additional, Helfrich, Miep, additional, Henrickson, Sarah E., additional, Holland, Steven M., additional, Hsu, Amy P., additional, Jyonouchi, Soma, additional, Kashef, Sara, additional, Kelsen, Judith, additional, Khalil, Maya, additional, Klein, Christoph, additional, Kobrynski, Lisa, additional, Kohn, Donald B., additional, Kracker, S., additional, Krueger, James G., additional, Lavoie, Pascal M., additional, Lehman, Heather K., additional, Leiding, Jennifer W., additional, Lenardo, Michael J., additional, Levy, Ofer, additional, Lim, Allison Pecha, additional, Lionakis, Michail S., additional, Lisco, Andrea, additional, Lougaris, Vassilios, additional, Lugo Reyes, Saul O., additional, Markert, M. Louise, additional, Marsh, Rebecca A., additional, McCarthy, Elizabeth A., additional, Meyts, Isabelle, additional, Milito, Cinzia, additional, Milner, Joshua D., additional, Ming, Jeffrey E., additional, Moshous, Despina, additional, Müller, Ludmila, additional, Navrazhina, Kristina, additional, Nichols, Kim E., additional, Notarangelo, Luigi D., additional, Oksenhendler, Eric, additional, Orange, Jordan S., additional, Paganelli, Roberto, additional, Pawelec, Graham, additional, Pentimalli, Tancredi Massimo, additional, Perez, Elena E., additional, Picard, Capucine, additional, Plebani, Alessandro, additional, Porras, Oscar, additional, Przespolewski, Amanda C., additional, Puel, Anne, additional, Pulvirenti, Federica, additional, Quinti, Isabella, additional, Rezaei, Nima, additional, Rijkers, Ger T., additional, Rosenthal, David Walter, additional, Rosenzweig, Sergio D., additional, Segal, Brahm H., additional, Seppänen, Mikko R.J., additional, Sereti, Irini, additional, Shcherbina, Anna, additional, Sobacchi, Cristina, additional, Squire, Jacqueline D., additional, Stepensky, Polina, additional, Su, Helen C., additional, Sullivan, Kathleen E., additional, Torgerson, Troy R., additional, Uzel, Gulbu, additional, van der Burg, Mirjam, additional, Villa, Anna, additional, Villartay, Jean-Pierre de, additional, Warnatz, Klaus, additional, Wasserman, Richard L., additional, Weemaes, Corry M.R., additional, Yu, Joyce E., additional, Zhang, Shen-Ying, additional, and Ziegler, John B., additional
- Published
- 2020
- Full Text
- View/download PDF
11. Isotype defects
- Author
-
van der Burg, Mirjam, primary, Dalm, Virgil A.S.H., additional, and Weemaes, Corry M.R., additional
- Published
- 2020
- Full Text
- View/download PDF
12. Effective “activated PI3Kδ syndrome”–targeted therapy with the PI3Kδ inhibitor leniolisib
- Author
-
Rao, V. Koneti, Webster, Sharon, Dalm, Virgil A.S.H., Šedivá, Anna, van Hagen, P. Martin, Holland, Steven, Rosenzweig, Sergio D., Christ, Andreas D., Sloth, Birgitte, Cabanski, Maciej, Joshi, Aniket D., de Buck, Stefan, Doucet, Julie, Guerini, Danilo, Kalis, Christoph, Pylvaenaeinen, Ilona, Soldermann, Nicolas, Kashyap, Anuj, Uzel, Gulbu, Lenardo, Michael J., Patel, Dhavalkumar D., Lucas, Carrie L., and Burkhart, Christoph
- Published
- 2017
- Full Text
- View/download PDF
13. Did variants in inborn errors of immunity genes contribute to the extinction of Neanderthals?
- Author
-
Zhou, Zijun, M A Swagemakers, Sigrid, S Lourens, Mirthe, Suratannon, Narissara, J van der Spek, Peter, Dalm, Virgil A.S.H., A Dik, Willem, IJspeert, Hanna, van Hagen, P. Martin, Immunology, Pathology, and Internal Medicine
- Subjects
Immunology ,Immunology and Allergy ,General Medicine - Abstract
Background: Neanderthals were a species of archaic humans that became extinct around 40,000 years ago. Modern humans have inherited 1-6% of Neanderthal DNA as a result of interbreeding. These inherited Neanderthal genes have paradoxical influences, while some can provide protection to viral infections, some others are associated with autoimmune/auto-inflammatory diseases. Objective: We aim to investigate whether genetic variants with strong detrimental effects on the function of the immune system could have potentially contributed to the extinction of the Neanderthal population. Methods: We used the publically available genome information from an Altai Neanderthal and filtered for potentially damaging variants present in genes associated with inborn errors of immunity (IEI) and checked whether these variants were present in the genomes of the Denisovan, Vindija and Chagyrskaya Neanderthals. Results: We identified 24 homozygous variants and 15 heterozygous variants in IEI-related genes in the Altai. Neanderthal. Two homozygous variants in the UNC13D gene and one variant in the MOGS gene were present in all archaic genomes. Defects in the UNC13D gene are known to cause a severe and often fatal disease called. hemophagocytic lymphohistiocystosis (HLH). One of these variants p.(N943S) has been reported in patients with HLH. Variants in MOGS are associated with glycosylation defects in the immune system affecting the susceptibility for infections. Conclusion: Although the exact functional impact of these three variants needs further elucidation, we speculate that they could have resulted in an increased susceptibility to severe diseases and may have contributed to the extinction of Neanderthals after exposure to specific infections.
- Published
- 2022
14. A Transcriptomic Severity Classifier IMX-SEV-3b to Predict Mortality in Intensive Care Unit Patients with COVID-19:A Prospective Observational Pilot Study
- Author
-
Daenen, Katrijn, Tong-Minh, Kirby, Liesenfeld, Oliver, Stoof, Sara C.M., Huijben, Jilske A., Dalm, Virgil A.S.H., Gommers, Diederik, van Gorp, Eric C.M., Endeman, Henrik, Daenen, Katrijn, Tong-Minh, Kirby, Liesenfeld, Oliver, Stoof, Sara C.M., Huijben, Jilske A., Dalm, Virgil A.S.H., Gommers, Diederik, van Gorp, Eric C.M., and Endeman, Henrik
- Abstract
The prediction of disease outcomes in COVID-19 patients in the ICU is of critical importance, and the examination of host gene expressions is a promising tool. The 29-host mRNA Inflam-matix-Severity-3b (IMX-SEV-3b) classifier has been reported to predict mortality in emergency department COVID-19 patients and surgical ICU patients. The accuracy of the IMX-SEV-3b in predicting mortality in COVID-19 patients admitted to the ICU is yet unknown. Our aim was to investigate the accuracy of the IMX-SEV-3b in predicting the ICU mortality of COVID-19 patients. In addition, we assessed the predictive performance of routinely measured biomarkers and the Sequential Organ Failure Assessment (SOFA) score as well. This was a prospective observational study enrolling COVID-19 patients who received mechanical ventilation on the ICU of the Erasmus MC, the Netherlands. The IMX-SEV-3b scores were generated by amplifying 29 host response genes from blood collected in PAXgene® Blood RNA tubes. A severity score was provided, ranging from 0 to 1 for increasing disease severity. The primary outcome was the accuracy of the IMX-SEV-3b in predicting ICU mortality, and we calculated the AUROC of the IMX-SEV-3b score, the biomarkers C-reactive protein (CRP), D-dimer, ferritin, leukocyte count, interleukin-6 (IL-6), lactate dehydrogenase (LDH), neutrophil-to-lymphocyte ratio (NLR), procalcitonin (PCT) and the SOFA score. A total of 53 patients were included between 1 March and 30 April 2020, with 47 of them being included within 72 h of their admission to the ICU. Of these, 18 (34%) patients died during their ICU stay, and the IMX-SEV-3b scores were significantly higher in non-survivors compared to survivors (0.65 versus 0.57, p = 0.05). The Area Under the Receiver Operating Characteristic Curve (AUROC) for prediction of ICU mortality by the IMX-SEV-3b was 0.65 (0.48–0.82). The AUROCs of the biomarkers ranged from 0.52 to 0.66, and the SOFA score had an AUROC of 0.81 (0.69–0.93). Th
- Published
- 2023
15. Soluble Interleukin-2 Receptor/White Blood Cell Ratio Reflects Granulomatous Disease Progression in Common Variable Immune Deficiency
- Author
-
van Stigt, Astrid C., Dalm, Virgil A.S.H., Nagtzaam, Nicole M.A., van Hagen, P. Martin, Dik, Willem A., IJspeert, Hanna, van Stigt, Astrid C., Dalm, Virgil A.S.H., Nagtzaam, Nicole M.A., van Hagen, P. Martin, Dik, Willem A., and IJspeert, Hanna
- Published
- 2023
16. Optimal Dosing and Timing of High-Dose Corticosteroid Therapy in Hospitalized Patients With COVID-19:Study Protocol for a Retrospective Observational Multicenter Study (SELECT)
- Author
-
Daenen, Katrijn, Huijben, Jilske A., Boyd, Anders, Bos, Lieuwe D.J., Stoof, Sara C.M., van Willigen, Hugo, Gommers, Diederik A.M.P.J., Moeniralam, Hazra S., den Uil, Corstiaan A., Juffermans, Nicole P., Kant, Merijn, Valkenburg, Abraham J., Pillay, Janesh, van Meenen, David M.P., Paulus, Frederique, Schultz, Marcus J., Dalm, Virgil A.S.H., van Gorp, Eric C.M., Schinkel, Janke, Endeman, Henrik, Daenen, Katrijn, Huijben, Jilske A., Boyd, Anders, Bos, Lieuwe D.J., Stoof, Sara C.M., van Willigen, Hugo, Gommers, Diederik A.M.P.J., Moeniralam, Hazra S., den Uil, Corstiaan A., Juffermans, Nicole P., Kant, Merijn, Valkenburg, Abraham J., Pillay, Janesh, van Meenen, David M.P., Paulus, Frederique, Schultz, Marcus J., Dalm, Virgil A.S.H., van Gorp, Eric C.M., Schinkel, Janke, and Endeman, Henrik
- Abstract
Background: In hospitalized patients with COVID-19, the dosing and timing of corticosteroids vary widely. Low-dose dexamethasone therapy reduces mortality in patients requiring respiratory support, but it remains unclear how to treat patients when this therapy fails. In critically ill patients, high-dose corticosteroids are often administered as salvage late in the disease course, whereas earlier administration may be more beneficial in preventing disease progression. Previous research has revealed that increased levels of various biomarkers are associated with mortality, and whole blood transcriptome sequencing has the ability to identify host factors predisposing to critical illness in patients with COVID-19. Objective: Our goal is to determine the most optimal dosing and timing of corticosteroid therapy and to provide a basis for personalized corticosteroid treatment regimens to reduce morbidity and mortality in hospitalized patients with COVID-19. Methods: This is a retrospective, observational, multicenter study that includes adult patients who were hospitalized due to COVID-19 in the Netherlands. We will use the differences in therapeutic strategies between hospitals (per protocol high-dose corticosteroids or not) over time to determine whether high-dose corticosteroids have an effect on the following outcome measures: mechanical ventilation or high-flow nasal cannula therapy, in-hospital mortality, and 28-day survival. We will also explore biomarker profiles in serum and bronchoalveolar lavage fluid and use whole blood transcriptome analysis to determine factors that influence the relationship between high-dose corticosteroids and outcome. Existing databases that contain routinely collected electronic data during ward and intensive care admissions, as well as existing biobanks, will be used. We will apply longitudinal modeling appropriate for each data structure to answer the research questions at hand. Results: As of April 2023, data have been collected f
- Published
- 2023
17. A beacon in the dark:COVID-19 course in CVID patients from two European countries: Different approaches, similar outcomes
- Author
-
Milito, Cinzia, Firinu, Davide, Bez, Patrick, Villa, Annalisa, Punziano, Alessandra, Lagnese, Gianluca, Costanzo, Giulia, van Leeuwen, Leanne P.M., Piazza, Beatrice, Deiana, Carla Maria, d’Ippolito, Giancarlo, Del Giacco, Stefano Renato, Rattazzi, Marcello, Spadaro, Giuseppe, Quinti, Isabella, Scarpa, Riccardo, Dalm, Virgil A.S.H., Cinetto, Francesco, Milito, Cinzia, Firinu, Davide, Bez, Patrick, Villa, Annalisa, Punziano, Alessandra, Lagnese, Gianluca, Costanzo, Giulia, van Leeuwen, Leanne P.M., Piazza, Beatrice, Deiana, Carla Maria, d’Ippolito, Giancarlo, Del Giacco, Stefano Renato, Rattazzi, Marcello, Spadaro, Giuseppe, Quinti, Isabella, Scarpa, Riccardo, Dalm, Virgil A.S.H., and Cinetto, Francesco
- Abstract
Background: CVID patients present an increased risk of prolonged SARS-CoV-2 infection and re-infection and a higher COVID-19-related morbidity and mortality compared to the general population. Since 2021, different therapeutic and prophylactic strategies have been employed in vulnerable groups (vaccination, SARS-CoV-2 monoclonal antibodies and antivirals). The impact of treatments over the last 2 years has not been explored in international studies considering the emergence of viral variants and different management between countries. Methods: A multicenter retrospective/prospective real-life study comparing the prevalence and outcomes of SARS-CoV-2 infection between a CVID cohort from four Italian Centers (IT-C) and one cohort from the Netherlands (NL-C), recruiting 773 patients. Results: 329 of 773 CVID patients were found positive for SARS-CoV-2 infection between March 1st, 2020 and September 1st 2022. The proportion of CVID patients infected was comparable in both national sub-cohorts. During all waves, chronic lung disease, “complicated” phenotype, chronic immunosuppressive treatment and cardiovascular comorbidities impacted on hospitalization, whereas risk factors for mortality were older age, chronic lung disease, and bacterial superinfections. IT-C patients were significantly more often treated, both with antivirals and mAbs, than NL-C patients. Outpatient treatment, available only in Italy, started from the Delta wave. Despite this, no significant difference was found for COVID-19 severity between the two cohorts. However, pooling together specific SARS-CoV-2 outpatient treatments (mAbs and antivirals), we found a significant effect on the risk of hospitalization starting from Delta wave. Vaccination with ≥ 3 doses shortened RT-PCR positivity, with an additional effect only in patients receiving antivirals. Conclusions: The two sub-cohorts had similar COVID-19 outcomes despite different treatment approaches. This points out that spe
- Published
- 2023
18. The Association of Serum Immunoglobulins with Risk of Cardiovascular Disease and Mortality:the Rotterdam Study
- Author
-
Khan, Samer R., Dalm, Virgil A.S.H., Ikram, M. Kamran, Peeters, Robin P., van Hagen, P. Martin, Kavousi, Maryam, Chaker, Layal, Khan, Samer R., Dalm, Virgil A.S.H., Ikram, M. Kamran, Peeters, Robin P., van Hagen, P. Martin, Kavousi, Maryam, and Chaker, Layal
- Abstract
Purpose: Inflammation is implicated in cardiovascular disease (CVD), but the association of total serum immunoglobulin (Ig) A, G, and M with CVD across the whole spectrum of atherosclerosis in community-dwelling elderly is unknown. Methods: This study was embedded in the Rotterdam Study, an ongoing population-based cohort study. We performed Cox regression for the associations of Igs with incident atherosclerotic CVD (ACVD; composite of myocardial infarction, revascularization, and stroke), cardiovascular mortality, and all-cause mortality, and multinomial logistic regression for the association between Igs and coronary artery calcification (CAC) scores. We adjusted for age, sex, lifestyle, and cardiovascular risk factors and presented results per standard deviation increase. Results: We included 8767 participants (median age 62.2 years, 57% women). Higher IgG was associated with an increased ACVD risk (hazard ratio [HR]: 1.08; 95% confidence interval [95% CI]: 1.01–1.15). Higher IgA and IgG were associated with an increased cardiovascular mortality risk, mainly within Ig reference ranges, and with an increased all-cause mortality risk, although less marked. Higher IgA was associated with severe atherosclerosis, i.e., CAC score > 400 (odds ratio: 1.29; 95% CI: 1.03–1.62), while for higher IgG a trend was seen with severe atherosclerosis. Conclusion: In middle-aged and older individuals from the general population, higher serum IgA and IgG, but not IgM, are associated with CVD, cardiovascular mortality, and severe atherosclerosis, particularly within Ig reference ranges and independent of serum C-reactive protein. Future studies are needed to elucidate potential causality of the reported associations.
- Published
- 2023
19. Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers
- Author
-
Sablerolles, Roos S.G., Rietdijk, Wim J.R., Goorhuis, Abraham, Postma, Douwe F., Visser, Leo G., Schmitz, Katharina S., Geers, Daryl, Bogers, Susanne, van Haren, Eva, Koopmans, Marion P.G., Dalm, Virgil A.S.H., Kootstra, Neeltje A., Huckriede, Anke L.W., Akkerman, Renate, Beukema, Martin, Lafeber, Melvin, van Baarle, Debbie, de Vries, Rory D., van der Kuy, P. Hugo M., GeurtsvanKessel, Corine H., Sablerolles, Roos S.G., Rietdijk, Wim J.R., Goorhuis, Abraham, Postma, Douwe F., Visser, Leo G., Schmitz, Katharina S., Geers, Daryl, Bogers, Susanne, van Haren, Eva, Koopmans, Marion P.G., Dalm, Virgil A.S.H., Kootstra, Neeltje A., Huckriede, Anke L.W., Akkerman, Renate, Beukema, Martin, Lafeber, Melvin, van Baarle, Debbie, de Vries, Rory D., van der Kuy, P. Hugo M., and GeurtsvanKessel, Corine H.
- Abstract
The emergence of SARS-CoV-2 variants raised questions regarding the durability of immune responses after homologous or heterologous boosters after Ad26.COV2.S-priming. We found that SARS-CoV-2-specific binding antibodies, neutralizing antibodies, and T cells are detectable 5 months after boosting, although waning of antibodies and limited cross-reactivity with Omicron BA.1 was observed.
- Published
- 2023
20. Correction: Biallelic PAX5 mutations cause hypogammaglobulinemia, sensorimotor deficits, and autism spectrum disorder
- Author
-
Kaiser, Fabian M.P., primary, Gruenbacher, Sarah, additional, Oyaga, Maria Roa, additional, Nio, Enzo, additional, Jaritz, Markus, additional, Sun, Qiong, additional, van der Zwaag, Wietske, additional, Kreidl, Emanuel, additional, Zopf, Lydia M., additional, Dalm, Virgil A.S.H., additional, Pel, Johan, additional, Gaiser, Carolin, additional, van der Vliet, Rick, additional, Wahl, Lucas, additional, Rietman, André, additional, Hill, Louisa, additional, Leca, Ines, additional, Driessen, Gertjan, additional, Laffeber, Charlie, additional, Brooks, Alice, additional, Katsikis, Peter D., additional, Lebbink, Joyce H.G., additional, Tachibana, Kikuë, additional, van der Burg, Mirjam, additional, De Zeeuw, Chris I., additional, Badura, Aleksandra, additional, and Busslinger, Meinrad, additional
- Published
- 2022
- Full Text
- View/download PDF
21. Interim Analysis of Safety and Hematological Parameters of an Ongoing Long-Term Open-Label Extension Study of Investigational PI3Kδ Inhibitor Leniolisib for Patients with Activated PI3K Delta Syndrome (APDS) through December 2021
- Author
-
Rao, V. Koneti, primary, Webster, Sharon, additional, Sediva, Anna, additional, Plebani, Alessandro, additional, Schuetz, Catharina, additional, Shcherbina, Anna, additional, Dalm, Virgil A.S.H., additional, Trizzino, Antonino, additional, Zharankova, Yulia, additional, Kulm, Elaine, additional, Orpia, Alanvin, additional, Chirombo Kluczynski, Lavenda, additional, Körholz, Julia, additional, Lougaris, Vassilios, additional, Rodina, Yulia, additional, Kucher, Klaus, additional, Radford, Kath, additional, Bradt, Jason, additional, and Uzel, Gulbu, additional
- Published
- 2022
- Full Text
- View/download PDF
22. Did variants in inborn errors of immunity genes contribute to the extinction of Neanderthals?
- Author
-
Zhou, Zijun, primary, Swagemakers, Sigrid M.A, additional, Lourens, Mirthe S., additional, Suratannon, Narissara, additional, van der Spek, Peter J., additional, Dalm, Virgil A.S.H., additional, Dik, Willem A., additional, IJspeert, Hanna, additional, and van Hagen, P. Martin, additional
- Published
- 2022
- Full Text
- View/download PDF
23. Treatment Experiences with Intravenous Immunoglobulins, Ixekizumab, Dupilumab, and Anakinra in Netherton Syndrome: A Case Series
- Author
-
Ragamin, Aviël, primary, Nouwen, Anouk E.M., additional, Dalm, Virgil A.S.H., additional, van Mierlo, Minke M.F., additional, Lincke, Carsten R., additional, and Pasmans, Suzanne G.M.A., additional
- Published
- 2022
- Full Text
- View/download PDF
24. The association of serum immunoglobulins with risk of cardiovascular disease and mortality: the Rotterdam Study
- Author
-
Khan, Samer R., primary, Dalm, Virgil A.S.H., additional, Ikram, M. Kamran, additional, Peeters, Robin P., additional, Hagen, P. Martin van, additional, Kavousi, Maryam, additional, and Chaker, Layal, additional
- Published
- 2022
- Full Text
- View/download PDF
25. Biallelic PAX5 mutations cause hypogammaglobulinemia, sensorimotor deficits, and autism spectrum disorder
- Author
-
Kaiser, Fabian M.P., primary, Gruenbacher, Sarah, additional, Oyaga, Maria Roa, additional, Nio, Enzo, additional, Jaritz, Markus, additional, Sun, Qiong, additional, van der Zwaag, Wietske, additional, Kreidl, Emanuel, additional, Zopf, Lydia M., additional, Dalm, Virgil A.S.H., additional, Pel, Johan, additional, Gaiser, Carolin, additional, van der Vliet, Rick, additional, Wahl, Lucas, additional, Rietman, André, additional, Hill, Louisa, additional, Leca, Ines, additional, Driessen, Gertjan, additional, Laffeber, Charlie, additional, Brooks, Alice, additional, Katsikis, Peter D., additional, Lebbink, Joyce H.G., additional, Tachibana, Kikuë, additional, van der Burg, Mirjam, additional, De Zeeuw, Chris I., additional, Badura, Aleksandra, additional, and Busslinger, Meinrad, additional
- Published
- 2022
- Full Text
- View/download PDF
26. Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity
- Author
-
van Leeuwen, Leanne P.M., primary, GeurtsvanKessel, Corine H., additional, Ellerbroek, Pauline M., additional, de Bree, Godelieve J., additional, Potjewijd, Judith, additional, Rutgers, Abraham, additional, Jolink, Hetty, additional, van de Veerdonk, Frank, additional, van Gorp, Eric C.M., additional, de Wilt, Faye, additional, Bogers, Susanne, additional, Gommers, Lennert, additional, Geers, Daryl, additional, Bruns, Anke H.W., additional, Leavis, Helen L., additional, van Haga, Jelle W., additional, Lemkes, Bregtje A., additional, van der Veen, Annelou, additional, de Kruijf-Bazen, S.F.J., additional, van Paassen, Pieter, additional, de Leeuw, Karina, additional, van de Ven, Annick A.J.M., additional, Verbeek-Menken, Petra H., additional, van Wengen, Annelies, additional, Arend, Sandra M., additional, Ruten-Budde, Anja J., additional, van der Ent, Marianne W., additional, van Hagen, P. Martin, additional, Sanders, Rogier W., additional, Grobben, Marloes, additional, van der Straten, Karlijn, additional, Burger, Judith A., additional, Poniman, Meliawati, additional, Nierkens, Stefan, additional, van Gils, Marit J., additional, de Vries, Rory D., additional, and Dalm, Virgil A.S.H., additional
- Published
- 2022
- Full Text
- View/download PDF
27. Outcomes of Systemic Treatment in Children and Adults With Netherton Syndrome:A Systematic Review
- Author
-
Nouwen, Anouk E.M., Schappin, Renske, Nguyen, N. Tan, Ragamin, Aviël, Bygum, Anette, Bodemer, Christine, Dalm, Virgil A.S.H., Pasmans, Suzanne G.M.A., Nouwen, Anouk E.M., Schappin, Renske, Nguyen, N. Tan, Ragamin, Aviël, Bygum, Anette, Bodemer, Christine, Dalm, Virgil A.S.H., and Pasmans, Suzanne G.M.A.
- Abstract
Background: Comèl-Netherton syndrome (NS) is a rare disease caused by pathogenic variants in the SPINK5 gene, leading to severe skin barrier impairment and proinflammatory upregulation. Given the severity of the disease, treatment of NS is challenging. Current treatment regimens are mainly topical and supportive. Although novel systemic treatment options for NS have been suggested in recent literature, little is known about their outcomes. Objective: to provide an overview of systemic treatment options and their outcomes in adults and children with NS. Methods: Embase, MEDLINE, Web of Science, Cochrane Central Register of Controlled Trials, and Google Scholar were searched up to July 22, 2021. Empirical studies published in English language mentioning systemic treatment in NS were enrolled. Studies that did not define a treatment period or report at least one outcome were excluded. Methodological quality was evaluated by the Joanna Briggs Institute critical appraisal checklist for case reports or case series. Overall quality of evidence of the primary outcome, skin, was assessed by the GRADE approach. Results: 36 case series and case reports were included. The effects of 15 systemic therapies were described in 48 patients, of which 27 were children. Therapies included retinoids, prednisolone, cyclosporine, immunoglobulins, and biologicals. In retinoids both worsening (4/15 cases) and improvement (6/15 cases) of the skin was observed. Use of prednisolone and cyclosporine was only reported in one patient. Immunoglobulins (13/15 cases) and biologicals (18/21 cases) showed improvement of the skin. Certainty of evidence was rated as very low. Conclusion: NS is a rare disease, which is reflected in the scarce literature on systemic treatment outcomes in children and adults with NS. Studies showed large heterogeneity in outcome measures. Adverse events were scarcely reported. Long-term outcomes were reported in a minority of cases. Nonetheless, a general beneficial effe
- Published
- 2022
28. Blood myxovirus resistance protein-1 measurement in the diagnostic work-up of suspected COVID-19 infection in the emergency department
- Author
-
Tong-Minh, Kirby, van Hooijdonk, Samantha, Versnel, Marjan A., van Helden-Meeuwsen, Cornelia G., van Hagen, Petrus Martin, van Gorp, Eric C.M., Endeman, Henrik, van der Does, Yuri, Dalm, Virgil A.S.H., Dik, Willem A., Tong-Minh, Kirby, van Hooijdonk, Samantha, Versnel, Marjan A., van Helden-Meeuwsen, Cornelia G., van Hagen, Petrus Martin, van Gorp, Eric C.M., Endeman, Henrik, van der Does, Yuri, Dalm, Virgil A.S.H., and Dik, Willem A.
- Abstract
Introduction: Myxovirus resistance protein 1 (MxA) is a biomarker that is elevated in patients with viral infections. The goal of this study was to evaluate the diagnostic value of MxA in diagnosing COVID-19 infections in the emergency department (ED) patients. Methods: This was a single-center prospective observational cohort study including patients with a suspected COVID-19 infection. The primary outcome of this study was a confirmed COVID-19 infection by RT-PCR test. MxA was assessed using an enzyme immunoassay on whole blood and receiver operating chart and area under the curve (AUC) analysis was conducted. Sensitivity, specificity, negative predictive value, and positive predictive value of MxA on diagnosing COVID-19 at the optimal cut-off of MxA was determined. Results: In 2021, 100 patients were included. Of these patients, 77 patients had COVID-19 infection and 23 were non-COVID-19. Median MxA level was significantly higher (p <.001) in COVID-19 patients compared to non-COVID-19 patients, respectively 1933 and 0.1 ng/ml. The AUC of MxA on a confirmed COVID-19 infection was 0.941 (95% CI: 0.867–1.000). The optimal cut-off point of MxA was 252 ng/ml. At this cut-off point, the sensitivity of MxA on a confirmed COVID-19 infection was 94% (95% CI: 85%–98%) and the specificity was 91% (95% CI: 72%–99%). Conclusion: MxA accurately distinguishes COVID-19 infections from bacterial infections and noninfectious diagnoses in the ED in patients with a suspected COVID-19 infection. If the results can be validated, MxA could improve the diagnostic workup and patient flow in the ED.
- Published
- 2022
29. Serum Immunoglobulins, Pneumonia Risk, and Lung Function in Middle-Aged and Older Individuals:A Population-Based Cohort Study
- Author
-
Khan, Samer R., Vanoverschelde, Anna, Lahousse, Lies, Peeters, Robin P., van Hagen, P. Martin, Brusselle, Guy, Chaker, Layal, Dalm, Virgil A.S.H., Khan, Samer R., Vanoverschelde, Anna, Lahousse, Lies, Peeters, Robin P., van Hagen, P. Martin, Brusselle, Guy, Chaker, Layal, and Dalm, Virgil A.S.H.
- Abstract
Introduction: Immunoglobulins (Igs) play a pivotal role in host defense and prevention of pneumonia. Aging influences serum Ig levels, but the association between Igs and pneumonia in community-dwelling older individuals remains unknown. We evaluated the association of serum IgA, IgG, and IgM with pneumonia and lung function in middle-aged and older individuals. Methods: We performed Cox and negative binomial regression analyses for the association of Igs with incident pneumonia and pneumonia-related mortality, and recurrent pneumonia respectively. We performed logistic regression analyses for the association between Igs and lung function values. Associations were adjusted for age, sex, smoking, comorbidities, and serum C-reactive protein. Results: We included 8,766 participants (median age 62.2 years, 57% women, median follow-up 9.8 years). Higher IgA (hazard ratio [HR]: 1.15; 95% confidence interval [95% CI]: 1.00-1.32) and IgG (HR: 1.13; 95% CI: 1.06-1.19) were associated with an increased pneumonia risk. Higher IgG was associated with an increased risk of pneumonia-related mortality (HR: 1.08; 95% CI: 1.01-1.16) and recurrent pneumonia (incidence rate ratio: 1.04; 95% CI: 1.00-1.09). Higher IgA and IgG were also associated with lower forced expiratory volume in one second (FEV1), lower forced vital capacity (FVC), and an increased odds of preserved ratio impaired spirometry (PRISm, i.e. FEV1 <80% and FEV1/FVC ratio ≥70%). No association was seen with an obstructive spirometry pattern. Discussion: Higher serum IgA and IgG levels were associated with pneumonia, pneumonia-related mortality, and PRISm in middle-aged and older individuals from the general population. Future studies should validate our findings and elucidate underlying pathophysiology.
- Published
- 2022
30. Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity
- Author
-
van Leeuwen, Leanne P.M., GeurtsvanKessel, Corine H., Ellerbroek, Pauline M., de Bree, Godelieve J., Potjewijd, Judith, Rutgers, Abraham, Jolink, Hetty, van de Veerdonk, Frank, van Gorp, Eric C.M., de Wilt, Faye, Bogers, Susanne, Gommers, Lennert, Geers, Daryl, Bruns, Anke H.W., Leavis, Helen L., van Haga, Jelle W., Lemkes, Bregtje A., van der Veen, Annelou, de Kruijf-Bazen, S. F.J., van Paassen, Pieter, de Leeuw, Karina, van de Ven, Annick A.J.M., Verbeek-Menken, Petra H., van Wengen, Annelies, Arend, Sandra M., Ruten-Budde, Anja J., van der Ent, Marianne W., van Hagen, P. Martin, Sanders, Rogier W., Grobben, Marloes, van der Straten, Karlijn, Burger, Judith A., Poniman, Meliawati, Nierkens, Stefan, van Gils, Marit J., de Vries, Rory D., Dalm, Virgil A.S.H., van Leeuwen, Leanne P.M., GeurtsvanKessel, Corine H., Ellerbroek, Pauline M., de Bree, Godelieve J., Potjewijd, Judith, Rutgers, Abraham, Jolink, Hetty, van de Veerdonk, Frank, van Gorp, Eric C.M., de Wilt, Faye, Bogers, Susanne, Gommers, Lennert, Geers, Daryl, Bruns, Anke H.W., Leavis, Helen L., van Haga, Jelle W., Lemkes, Bregtje A., van der Veen, Annelou, de Kruijf-Bazen, S. F.J., van Paassen, Pieter, de Leeuw, Karina, van de Ven, Annick A.J.M., Verbeek-Menken, Petra H., van Wengen, Annelies, Arend, Sandra M., Ruten-Budde, Anja J., van der Ent, Marianne W., van Hagen, P. Martin, Sanders, Rogier W., Grobben, Marloes, van der Straten, Karlijn, Burger, Judith A., Poniman, Meliawati, Nierkens, Stefan, van Gils, Marit J., de Vries, Rory D., and Dalm, Virgil A.S.H.
- Abstract
Background: Patients with inborn errors of immunity (IEI) are at increased risk of severe coronavirus disease-2019 (COVID-19). Effective vaccination against COVID-19 is therefore of great importance in this group, but little is known about the immunogenicity of COVID-19 vaccines in these patients. Objectives: We sought to study humoral and cellular immune responses after mRNA-1273 COVID-19 vaccination in adult patients with IEI. Methods: In a prospective, controlled, multicenter study, 505 patients with IEI (common variable immunodeficiency [CVID], isolated or undefined antibody deficiencies, X-linked agammaglobulinemia, combined B- and T-cell immunodeficiency, phagocyte defects) and 192 controls were included. All participants received 2 doses of the mRNA-1273 COVID-19 vaccine. Levels of severe acute respiratory syndrome coronavirus-2–specific binding antibodies, neutralizing antibodies, and T-cell responses were assessed at baseline, 28 days after first vaccination, and 28 days after second vaccination. Results: Seroconversion rates in patients with clinically mild antibody deficiencies and phagocyte defects were similar to those in healthy controls, but seroconversion rates in patients with more severe IEI, such as CVID and combined B- and T-cell immunodeficiency, were lower. Binding antibody titers correlated well to the presence of neutralizing antibodies. T-cell responses were comparable to those in controls in all IEI cohorts, with the exception of patients with CVID. The presence of noninfectious complications and the use of immunosuppressive drugs in patients with CVID were negatively correlated with the antibody response. Conclusions: COVID-19 vaccination with mRNA-1273 was immunogenic in mild antibody deficiencies and phagocyte defects and in most patients with combined B- and T-cell immunodeficiency and CVID. Lowest response was detected in patients with X-linked agammaglobulinemia and in patients with CVID with noninfectious complications. The assess
- Published
- 2022
31. Biallelic PAX5 mutations cause hypogammaglobulinemia, sensorimotor deficits, and autism spectrum disorder
- Author
-
Kaiser, Fabian M.P., Gruenbacher, Sarah, Oyaga, Maria Roa, Nio, Enzo, Jaritz, Markus, Sun, Qiong, van der Zwaag, Wietske, Kreidl, Emanuel, Zopf, Lydia M., Dalm, Virgil A.S.H., Pel, Johan, Gaiser, Carolin, van der Vliet, Rick, Wahl, Lucas, Rietman, André, Hill, Louisa, Leca, Ines, Driessen, Gertjan, Laffeber, Charlie, Brooks, Alice, Katsikis, Peter D., Lebbink, Joyce H.G., Tachibana, Kikuë, van der Burg, Mirjam, De Zeeuw, Chris I., Badura, Aleksandra, Busslinger, Meinrad, Kaiser, Fabian M.P., Gruenbacher, Sarah, Oyaga, Maria Roa, Nio, Enzo, Jaritz, Markus, Sun, Qiong, van der Zwaag, Wietske, Kreidl, Emanuel, Zopf, Lydia M., Dalm, Virgil A.S.H., Pel, Johan, Gaiser, Carolin, van der Vliet, Rick, Wahl, Lucas, Rietman, André, Hill, Louisa, Leca, Ines, Driessen, Gertjan, Laffeber, Charlie, Brooks, Alice, Katsikis, Peter D., Lebbink, Joyce H.G., Tachibana, Kikuë, van der Burg, Mirjam, De Zeeuw, Chris I., Badura, Aleksandra, and Busslinger, Meinrad
- Abstract
The genetic causes of primary antibody deficiencies and autism spectrum disorder (ASD) are largely unknown. Here, we report a patient with hypogammaglobulinemia and ASD who carries biallelic mutations in the transcription factor PAX5. A patient-specific Pax5 mutant mouse revealed an early B cell developmental block and impaired immune responses as the cause of hypogammaglobulinemia. Pax5 mutant mice displayed behavioral deficits in all ASD domains. The patient and the mouse model showed aberrant cerebellar foliation and severely impaired sensorimotor learning. PAX5 deficiency also caused profound hypoplasia of the substantia nigra and ventral tegmental area due to loss of GABAergic neurons, thus affecting two midbrain hubs, controlling motor function and reward processing, respectively. Heterozygous Pax5 mutant mice exhibited similar anatomic and behavioral abnormalities. Lineage tracing identified Pax5 as a crucial regulator of cerebellar morphogenesis and midbrain GABAergic neurogenesis. These findings reveal new roles of Pax5 in brain development and unravel the underlying mechanism of a novel immunological and neurodevelopmental syndrome.
- Published
- 2022
32. Psychological Symptoms in Primary Immunodeficiencies:a Common Comorbidity?
- Author
-
Manusama, Olivia R., van Beveren, Nico J.M., van Hagen, P. Martin, Drexhage, Hemmo A., Dalm, Virgil A.S.H., Manusama, Olivia R., van Beveren, Nico J.M., van Hagen, P. Martin, Drexhage, Hemmo A., and Dalm, Virgil A.S.H.
- Published
- 2022
33. Clinical features and immune-related protein patterns of anti-MDA5 positive clinically amyopathic dermatomyositis Dutch patients
- Author
-
MS Interne Geneeskunde, CTI Bont, Infection & Immunity, CTI, CTI Computational Immunology Core, UMC Utrecht Holding, Longziekten, Arts Assistenten Longziekten, CDL Patiëntenzorg MI, CTI Research, Cancer, Hensgens, Marjolein P.M., Delemarre, Eveline M., Drylewicz, Julia, Voortman, Mareye, Krol, Roline M., Dalm, Virgil A.S.H., Miedema, Jelle R., Wiertz, Ivo, Grutters, Jan, Limper, Maarten, Nierkens, Stefan, Leavis, Helen L., MS Interne Geneeskunde, CTI Bont, Infection & Immunity, CTI, CTI Computational Immunology Core, UMC Utrecht Holding, Longziekten, Arts Assistenten Longziekten, CDL Patiëntenzorg MI, CTI Research, Cancer, Hensgens, Marjolein P.M., Delemarre, Eveline M., Drylewicz, Julia, Voortman, Mareye, Krol, Roline M., Dalm, Virgil A.S.H., Miedema, Jelle R., Wiertz, Ivo, Grutters, Jan, Limper, Maarten, Nierkens, Stefan, and Leavis, Helen L.
- Published
- 2022
34. Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity
- Author
-
KTO Office, MS Interne Geneeskunde, Infection & Immunity, MS Reumatologie/Immunologie/Infectie, Unit Opleiding Aios, CTI, CDL Patiëntenzorg MI, CTI Research, Cancer, van Leeuwen, Leanne P.M., GeurtsvanKessel, Corine H., Ellerbroek, Pauline M., de Bree, Godelieve J., Potjewijd, Judith, Rutgers, Abraham, Jolink, Hetty, van de Veerdonk, Frank, van Gorp, Eric C.M., de Wilt, Faye, Bogers, Susanne, Gommers, Lennert, Geers, Daryl, Bruns, Anke H.W., Leavis, Helen L., van Haga, Jelle W., Lemkes, Bregtje A., van der Veen, Annelou, de Kruijf-Bazen, S. F.J., van Paassen, Pieter, de Leeuw, Karina, van de Ven, Annick A.J.M., Verbeek-Menken, Petra H., van Wengen, Annelies, Arend, Sandra M., Ruten-Budde, Anja J., van der Ent, Marianne W., van Hagen, P. Martin, Sanders, Rogier W., Grobben, Marloes, van der Straten, Karlijn, Burger, Judith A., Poniman, Meliawati, Nierkens, Stefan, van Gils, Marit J., de Vries, Rory D., Dalm, Virgil A.S.H., KTO Office, MS Interne Geneeskunde, Infection & Immunity, MS Reumatologie/Immunologie/Infectie, Unit Opleiding Aios, CTI, CDL Patiëntenzorg MI, CTI Research, Cancer, van Leeuwen, Leanne P.M., GeurtsvanKessel, Corine H., Ellerbroek, Pauline M., de Bree, Godelieve J., Potjewijd, Judith, Rutgers, Abraham, Jolink, Hetty, van de Veerdonk, Frank, van Gorp, Eric C.M., de Wilt, Faye, Bogers, Susanne, Gommers, Lennert, Geers, Daryl, Bruns, Anke H.W., Leavis, Helen L., van Haga, Jelle W., Lemkes, Bregtje A., van der Veen, Annelou, de Kruijf-Bazen, S. F.J., van Paassen, Pieter, de Leeuw, Karina, van de Ven, Annick A.J.M., Verbeek-Menken, Petra H., van Wengen, Annelies, Arend, Sandra M., Ruten-Budde, Anja J., van der Ent, Marianne W., van Hagen, P. Martin, Sanders, Rogier W., Grobben, Marloes, van der Straten, Karlijn, Burger, Judith A., Poniman, Meliawati, Nierkens, Stefan, van Gils, Marit J., de Vries, Rory D., and Dalm, Virgil A.S.H.
- Published
- 2022
35. Clinical characteristics and outcome of immunocompromised patients with COVID-19 caused by the Omicron variant: a prospective observational study
- Author
-
Malahe, S. Reshwan K., primary, Hoek, Rogier A.S., additional, Dalm, Virgil A.S.H., additional, Broers, Annoek E.C., additional, den Hoed, Caroline M., additional, Manintveld, Olivier C., additional, Baan, Carla C., additional, van Deuzen, Charlotte M., additional, Papageorgiou, Grigorios, additional, Bax, Hannelore I., additional, Van Kampen, Jeroen J., additional, Hellemons, Merel E., additional, Kho, Marcia M.L., additional, de Vries, Rory D., additional, Molenkamp, Richard, additional, Reinders, Marlies E.J., additional, and Rijnders, Bart J.A., additional
- Published
- 2022
- Full Text
- View/download PDF
36. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV: a nationwide prospective cohort study in the Netherlands
- Author
-
Hensley, Kathryn S., primary, Jongkees, Marlou J., additional, Geers, Daryl, additional, GeurtsvanKessel, Corine H., additional, Mueller, Yvonne M., additional, Dalm, Virgil A.S.H., additional, Papageorgiou, Grigorios, additional, Steggink, Hanka, additional, Gorska, Alicja, additional, Bogers, Susanne, additional, den Hollander, Jan G., additional, Bierman, Wouter F.W., additional, Gelinck, Luc B.S., additional, Schippers, Emile F., additional, Ammerlaan, Heidi S.M., additional, van der Valk, Marc, additional, van Vonderen, Marit G.A., additional, Delsing, Corine E., additional, Gisolf, Elisabeth H., additional, Bruns, Anke H.W., additional, Lauw, Fanny N., additional, Berrevoets, Marvin A.H., additional, Sigaloff, Kim C.E., additional, Soetekouw, Robert, additional, Branger, Judith, additional, de Mast, Quirijn, additional, Lammers, Adriana J.J., additional, Lowe, Selwyn H., additional, de Vries, Rory D., additional, Katsikis, Peter D., additional, Rijnders, Bart J.A., additional, Brinkman, Kees, additional, Roukens, Anna H.E., additional, and Rokx, Casper, additional
- Published
- 2022
- Full Text
- View/download PDF
37. Association between serum IgG levels and time to first antibiotic prescription in COPD patients
- Author
-
Vanoverschelde, Anna, primary, Khan, Samer R., additional, Dalm, Virgil A.S.H., additional, Chaker, Layal, additional, Brusselle, Guy, additional, Stricker, Bruno H., additional, and Lahousse, Lies, additional
- Published
- 2022
- Full Text
- View/download PDF
38. Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming
- Author
-
Sablerolles, Roos S.G., primary, Rietdijk, Wim J.R., additional, Goorhuis, Abraham, additional, Postma, Douwe F., additional, Visser, Leo G., additional, Geers, Daryl, additional, Schmitz, Katharina S., additional, Garcia Garrido, Hannah M., additional, Koopmans, Marion P.G., additional, Dalm, Virgil A.S.H., additional, Kootstra, Neeltje A., additional, Huckriede, Anke L.W., additional, Lafeber, Melvin, additional, van Baarle, Debbie, additional, GeurtsvanKessel, Corine H., additional, de Vries, Rory D., additional, and van der Kuy, P. Hugo M., additional
- Published
- 2022
- Full Text
- View/download PDF
39. The association of serum immunoglobulins with cognition and dementia: The Rotterdam Study
- Author
-
Khan, Samer R., primary, Yaqub, Amber, additional, Wolters, Frank J., additional, Ikram, M. Kamran, additional, Dalm, Virgil A.S.H., additional, Chaker, Layal, additional, and Ikram, M. Arfan, additional
- Published
- 2021
- Full Text
- View/download PDF
40. Activated PI3Kδ syndrome, an immunodeficiency disorder, leads to sensorimotor deficits recapitulated in a murine model
- Author
-
Serra, Ines, primary, Manusama, Olivia R., additional, Kaiser, Fabian M.P., additional, Floriano, Izi Izumi, additional, Wahl, Lucas, additional, van der Zalm, Christian, additional, IJspeert, Hanna, additional, van Hagen, P. Martin, additional, van Beveren, Nico J.M., additional, Arend, Sandra M., additional, Okkenhaug, Klaus, additional, Pel, Johan J.M., additional, Dalm, Virgil A.S.H., additional, and Badura, Aleksandra, additional
- Published
- 2021
- Full Text
- View/download PDF
41. Serum immunoglobulins and biomarkers of dementia: A population‐based study
- Author
-
Yaqub, Amber, primary, Khan, Samer R., additional, Wolters, Frank J., additional, Vernooij, Meike W., additional, Dalm, Virgil A.S.H., additional, Ikram, M. Arfan, additional, and Chaker, Layal, additional
- Published
- 2021
- Full Text
- View/download PDF
42. Histamine induces NF-κB controlled cytokine secretion by orbital fibroblasts via histamine receptor type-1
- Author
-
Virakul, Sita, Phetsuksiri, Tanachaporn, van Holten-Neelen, Conny, Schrijver, Benjamin, van Steensel, Leendert, Dalm, Virgil A.S.H., Paridaens, Dion, van den Bosch, Willem A., van Hagen, Martin P., and Dik, Willem A.
- Published
- 2016
- Full Text
- View/download PDF
43. Treatment Experiences with Intravenous Immunoglobulins, Ixekizumab, Dupilumab, and Anakinra in Netherton Syndrome: A Case Series.
- Author
-
Ragamin, Aviël, Nouwen, Anouk E.M., Dalm, Virgil A.S.H., van Mierlo, Minke M.F., Lincke, Carsten R., and Pasmans, Suzanne G.M.A.
- Subjects
INTRAVENOUS immunoglobulins ,DUPILUMAB ,ANAKINRA ,ADVERSE health care events ,BLOOD testing - Abstract
Background: Netherton syndrome (NS) is a rare potential life-threatening disorder that causes severe defects to the skin barrier. No effective treatment options are available for patients with NS and current therapy is mostly supportive. The effects of intravenous immunoglobulins (IVIGs), ixekizumab, and dupilumab have scarcely been reported. Additionally, the role of anakinra in patients with NS has never been investigated. Objectives: The objective was to report our experiences of treatment with IVIG, ixekizumab, dupi-lumab, and anakinra in patients with NS. Methods: A retrospective case series, including 5 patients with NS, was performed in a tertiary referral hospital between 2016 and 2021. Patients were treated with IVIG, ixekizumab, dupilumab, and/or anakinra. Long-term experiences with treatment regimens and adverse events requiring medical attention were reported. Results: IVIG, ixekizumab, dupilumab, and anakinra were well tolerated with no severe adverse events. The 2 patients that received IVIG showed clinical response for 6 months and 2.5 years. Ixekizumab was effective in 1 of our patients for 3.5 years, while in another patient ixekizumab lost its effect after 1.5 years. Dupilumab treatment did not result in persistent improvement of NS-related skin symptoms in 1 patient. Anakinra showed physician-assessed clinical response during the first months of treatment in 4 patients with NS. During anakinra treatment, no changes in blood levels of IL-1β, IL-6, and TNF-α levels were measured at routine blood examinations. Conclusions: This case series suggests that the use of IVIG, ixekizumab, dupilumab, and anakinra in NS is safe and moderately effective on the short term. On the long term, a decline in effect was observed. Our experiences may help clinicians and researchers to provide adequate care and develop treatment for these severely affected patients. More international research, especially on the long term, is needed to determine if and which patients benefit most from the emerging therapies for NS. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
44. Patients with Chromosome 11q-abberations are Characterized by a Combined Primary Immunodeficiency Involving Both B- and T-lymphocytes
- Author
-
Huisman, Elisabeth Janneke, primary, Brooimans, A. Rick, additional, Mayer, Samone, additional, Joosten, Marieke, additional, de Bont, Louis, additional, Dekker, Mariëlle, additional, Rammeloo, Elisabeth L.M., additional, Smiers, Frans J., additional, Hagen, P. Martin Van, additional, Zwaan, C Michel, additional, de Haas, Masja, additional, Cnossen, Marjon H., additional, and Dalm, Virgil A.S.H., additional
- Published
- 2021
- Full Text
- View/download PDF
45. Inflammatory bowel disease in primary immunodeficiency disorders is a heterogeneous clinical entity requiring an individualized treatment strategy: A systematic review
- Author
-
Both, Tim, primary, Dalm, Virgil A.S.H., additional, Richardson, Savannah A., additional, van Schie, Naïma, additional, van den Broek, Luuk M., additional, de Vries, Annemarie C., additional, van Hagen, P. Martin, additional, and Rombach, Saskia M., additional
- Published
- 2021
- Full Text
- View/download PDF
46. Platelet-Derived Growth Factor: A Key Factor in the Pathogenesis of Gravesʼ Ophthalmopathy and Potential Target for Treatment
- Author
-
Virakul, Sita, van Steensel, Leendert, Dalm, Virgil A.S.H., Paridaens, Dion, van Hagen, Martin P., and Dik, Willem A.
- Published
- 2014
- Full Text
- View/download PDF
47. Three Patients With Disseminated Mycobacterial Infections Due to Severe Defects in Interferon Gamma Receptor Signaling: A Challenging Diagnosis
- Author
-
Zhou, Zijun, primary, Hollink, Iris H.I.M., additional, Bouman, Arjan, additional, Lourens, Mirthe S., additional, Brooimans, Rik A., additional, Ham, Tjakko J. van, additional, Fraaij, Pieter L.A., additional, Rossum, Annemarie M.C. van, additional, Zijtregtop, Eline A.M., additional, Dik, Willem A., additional, Dalm, Virgil A.S.H., additional, Hagen, P. Martin van, additional, IJspeert, Hanna, additional, and Vermont, Clementien L., additional
- Published
- 2021
- Full Text
- View/download PDF
48. Azacytidine Treatment for VEXAS Syndrome
- Author
-
Raaijmakers, Marc, Hermans, Maud, Aalbers, Anna, Rijken, Melissa, Dalm, Virgil A.S.H., van Daele, Paul, Valk, Peter, Raaijmakers, Marc, Hermans, Maud, Aalbers, Anna, Rijken, Melissa, Dalm, Virgil A.S.H., van Daele, Paul, and Valk, Peter
- Published
- 2021
49. Determinants of Serum Immunoglobulin Levels:A Systematic Review and Meta-Analysis
- Author
-
Khan, Samer R., van der Burgh, Anna C., Peeters, Robin P., van Hagen, P. Martin, Dalm, Virgil A.S.H., Chaker, Layal, Khan, Samer R., van der Burgh, Anna C., Peeters, Robin P., van Hagen, P. Martin, Dalm, Virgil A.S.H., and Chaker, Layal
- Abstract
Background: An up-to-date overview of determinants of serum immunoglobulins in adults is pivotal for clinical practice and research, but currently lacking. We therefore performed a systematic review and meta-analysis to identify determinants of serum immunoglobulin levels. Methods: Embase, Web of Science, Medline, Cochrane, and Google Scholar were searched from inception to July 11th, 2019 for articles reporting on determinants of serum immunoglobulin A, G or M (IgA, IgG or IgM) in adult humans. Random and fixed effect models were applied to obtain pooled mean differences (MDs) and 95% confidence intervals (CIs) for the association of age and sex with serum immunoglobulins. Results: We retrieved 117 articles reporting on determinants of serum immunoglobulins, of which 28 could be meta-analyzed. Older compared to younger individuals had higher IgA (MD: 0.38; CI: 0.18 – 0.58), but lower IgM levels (MD: -0.40; 95%: -0.66 – -0.14). Men had higher IgA (MD: 0.22; CI: 0.03 – 0.42), but lower IgM levels (MD: -0.21; CI: -0.32 – -0.10) than women. Age and sex did not influence IgG. Caucasian ethnicity was associated with lower IgA, IgG, and IgM. Smoking and corticosteroid use were associated with lower IgG. Positive associations were reported of probiotics with IgG, alcohol with IgA, hypertension with IgA and IgG, and acute psychological stress with IgA, IgG, and IgM. Conclusions: Older age and male sex are associated with higher IgA, but lower IgM, and urge investigation of age- and sex-specific reference ranges of immunoglobulins. Other identified determinants were ethnicity, diet, lifestyle and cardio-metabolic factors.
- Published
- 2021
50. Treatment Strategies for GLILD in Common Variable Immunodeficiency:A Systematic Review
- Author
-
Lamers, Olivia A.C., Smits, Bas M., Leavis, Helen Louisa, de Bree, Godelieve J., Cunningham-Rundles, Charlotte, Dalm, Virgil A.S.H., Ho, Hsi En, Hurst, John R., IJspeert, Hanna, Prevaes, Sabine M.P.J., Robinson, Alex, van Stigt, Astrid C., Terheggen-Lagro, Suzanne, van de Ven, Annick A.J.M., Warnatz, Klaus, van de Wijgert, Janneke H.H.M., van Montfrans, Joris, Lamers, Olivia A.C., Smits, Bas M., Leavis, Helen Louisa, de Bree, Godelieve J., Cunningham-Rundles, Charlotte, Dalm, Virgil A.S.H., Ho, Hsi En, Hurst, John R., IJspeert, Hanna, Prevaes, Sabine M.P.J., Robinson, Alex, van Stigt, Astrid C., Terheggen-Lagro, Suzanne, van de Ven, Annick A.J.M., Warnatz, Klaus, van de Wijgert, Janneke H.H.M., and van Montfrans, Joris
- Abstract
Introduction: Besides recurrent infections, a proportion of patients with Common Variable Immunodeficiency Disorders (CVID) may suffer from immune dysregulation such as granulomatous-lymphocytic interstitial lung disease (GLILD). The optimal treatment of this complication is currently unknown. Experienced-based expert opinions have been produced, but a systematic review of published treatment studies is lacking. Goals: To summarize and synthesize the published literature on the efficacy of treatments for GLILD in CVID. Methods: We performed a systematic review using the PRISMA guidelines. Papers describing treatment and outcomes in CVID patients with radiographic and/or histologic evidence of GLILD were included. Treatment regimens and outcomes of treatment were summarized. Results: 6124 papers were identified and 42, reporting information about 233 patients in total, were included for review. These papers described case series or small, uncontrolled studies of monotherapy with glucocorticoids or other immunosuppressants, rituximab monotherapy or rituximab plus azathioprine, abatacept, or hematopoietic stem cell transplantation (HSCT). Treatment response rates varied widely. Cross-study comparisons were complicated because different treatment regimens, follow-up periods, and outcome measures were used. There was a trend towards more frequent GLILD relapses in patients treated with corticosteroid monotherapy when compared to rituximab-containing treatment regimens based on qualitative endpoints. HSCT is a promising alternative to pharmacological treatment of GLILD, because it has the potential to not only contain symptoms, but also to resolve the underlying pathology. However, mortality, especially among immunocompromised patients, is high. Conclusions: We could not draw definitive conclusions regarding optimal pharmacological treatment for GLILD in CVID from the current literature since quantitative, well-controlled evidence was lacking. While HSCT might be consi
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.